Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
TERT promoter (TERTp) mutations are important factors in papillary thyroid carcinomas (PTCs). They are associated with tumor aggressiveness, recurrence, and disease-specific mortality and their use in risk stratification of PTC patients has been proposed. In this study we investigated the prevalence...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/9/2647 |
id |
doaj-4b1c0cb749b34151addb185acc3960e1 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dagmara Rusinek Aleksandra Pfeifer Jolanta Krajewska Malgorzata Oczko-Wojciechowska Daria Handkiewicz-Junak Agnieszka Pawlaczek Jadwiga Zebracka-Gala Malgorzata Kowalska Renata Cyplinska Ewa Zembala-Nozynska Mykola Chekan Ewa Chmielik Aleksandra Kropinska Roman Lamch Beata Jurecka-Lubieniecka Barbara Jarzab Agnieszka Czarniecka |
spellingShingle |
Dagmara Rusinek Aleksandra Pfeifer Jolanta Krajewska Malgorzata Oczko-Wojciechowska Daria Handkiewicz-Junak Agnieszka Pawlaczek Jadwiga Zebracka-Gala Malgorzata Kowalska Renata Cyplinska Ewa Zembala-Nozynska Mykola Chekan Ewa Chmielik Aleksandra Kropinska Roman Lamch Beata Jurecka-Lubieniecka Barbara Jarzab Agnieszka Czarniecka Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients International Journal of Molecular Sciences TERTp mutation BRAF V600E papillary thyroid cancer |
author_facet |
Dagmara Rusinek Aleksandra Pfeifer Jolanta Krajewska Malgorzata Oczko-Wojciechowska Daria Handkiewicz-Junak Agnieszka Pawlaczek Jadwiga Zebracka-Gala Malgorzata Kowalska Renata Cyplinska Ewa Zembala-Nozynska Mykola Chekan Ewa Chmielik Aleksandra Kropinska Roman Lamch Beata Jurecka-Lubieniecka Barbara Jarzab Agnieszka Czarniecka |
author_sort |
Dagmara Rusinek |
title |
Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients |
title_short |
Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients |
title_full |
Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients |
title_fullStr |
Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients |
title_full_unstemmed |
Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients |
title_sort |
coexistence of tert promoter mutations and the braf v600e alteration and its impact on histopathological features of papillary thyroid carcinoma in a selected series of polish patients |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2018-09-01 |
description |
TERT promoter (TERTp) mutations are important factors in papillary thyroid carcinomas (PTCs). They are associated with tumor aggressiveness, recurrence, and disease-specific mortality and their use in risk stratification of PTC patients has been proposed. In this study we investigated the prevalence of TERTp mutations in a cohort of Polish patients with PTCs and the association of these mutations with histopathological factors, particularly in coexistence with the BRAF V600E mutation. A total of 189 consecutive PTC specimens with known BRAF mutational status were evaluated. TERTp mutations were detected in 8.5% of cases (16/189) with the C228T mutation being the most frequent. In six of the PTC specimens (3.2%), four additional TERTp alterations were found, which included one known polymorphism (rs2735943) and three previously unreported alterations. The association analysis revealed that the TERTp hotspot mutations were highly correlated with the presence of the BRAF V600E mutation and their coexistence was significantly associated with gender, advanced patient age, advanced disease stage, presence of lymph node metastases, larger tumor size, and tumor-capsule infiltration. While correlations were identified, the possibility of TERTp mutations being key molecular modulators responsible for PTC aggressiveness requires further studies. |
topic |
TERTp mutation BRAF V600E papillary thyroid cancer |
url |
http://www.mdpi.com/1422-0067/19/9/2647 |
work_keys_str_mv |
AT dagmararusinek coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT aleksandrapfeifer coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT jolantakrajewska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT malgorzataoczkowojciechowska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT dariahandkiewiczjunak coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT agnieszkapawlaczek coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT jadwigazebrackagala coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT malgorzatakowalska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT renatacyplinska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT ewazembalanozynska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT mykolachekan coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT ewachmielik coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT aleksandrakropinska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT romanlamch coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT beatajureckalubieniecka coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT barbarajarzab coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients AT agnieszkaczarniecka coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients |
_version_ |
1725285082094108672 |
spelling |
doaj-4b1c0cb749b34151addb185acc3960e12020-11-25T00:41:53ZengMDPI AGInternational Journal of Molecular Sciences1422-00672018-09-01199264710.3390/ijms19092647ijms19092647Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish PatientsDagmara Rusinek0Aleksandra Pfeifer1Jolanta Krajewska2Malgorzata Oczko-Wojciechowska3Daria Handkiewicz-Junak4Agnieszka Pawlaczek5Jadwiga Zebracka-Gala6Malgorzata Kowalska7Renata Cyplinska8Ewa Zembala-Nozynska9Mykola Chekan10Ewa Chmielik11Aleksandra Kropinska12Roman Lamch13Beata Jurecka-Lubieniecka14Barbara Jarzab15Agnieszka Czarniecka16Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Oncological and Reconstructive Surgery, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTERT promoter (TERTp) mutations are important factors in papillary thyroid carcinomas (PTCs). They are associated with tumor aggressiveness, recurrence, and disease-specific mortality and their use in risk stratification of PTC patients has been proposed. In this study we investigated the prevalence of TERTp mutations in a cohort of Polish patients with PTCs and the association of these mutations with histopathological factors, particularly in coexistence with the BRAF V600E mutation. A total of 189 consecutive PTC specimens with known BRAF mutational status were evaluated. TERTp mutations were detected in 8.5% of cases (16/189) with the C228T mutation being the most frequent. In six of the PTC specimens (3.2%), four additional TERTp alterations were found, which included one known polymorphism (rs2735943) and three previously unreported alterations. The association analysis revealed that the TERTp hotspot mutations were highly correlated with the presence of the BRAF V600E mutation and their coexistence was significantly associated with gender, advanced patient age, advanced disease stage, presence of lymph node metastases, larger tumor size, and tumor-capsule infiltration. While correlations were identified, the possibility of TERTp mutations being key molecular modulators responsible for PTC aggressiveness requires further studies.http://www.mdpi.com/1422-0067/19/9/2647TERTp mutationBRAF V600Epapillary thyroid cancer |